Mei Ri Jing Ji Xin Wen·2025-10-14 09:01Core Viewpoint - Fosun Pharma's subsidiary, Fosun Wanguo, has received notification from the National Medical Products Administration (NMPA) regarding the withdrawal of the registration application for the drug Dihydrosuccinimide Ruxolitinib Capsules, which is intended for the treatment of non-small cell lung cancer (ALK+ and ROS1+) [1] Summary by Categories Company Actions - The withdrawal of the registration application will not have a significant impact on the company's current performance [1] - Fosun Wanguo plans to improve the registration materials according to the latest technical requirements from the NMPA and will resubmit the drug registration application as soon as possible [1] Industry Context - The drug in question is an innovative small molecule chemical drug aimed at treating specific types of non-small cell lung cancer, indicating ongoing developments in targeted cancer therapies within the pharmaceutical industry [1]